Vertex Ventures HC — Full Portfolio
8 tracked investments · listed companies and verified rows first
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases.
BiotechHealthtechHouston, US
Guy DiPierro(Chief Operating Officer & Co-Founder)inSungjin Kim(Scientific Founder)John Sunwoo(Scientific Founder)Mark Frohlich(Executive Officer, Director)Mark W. Frohlich(Chief Executive Officer)Stefanie Mandl-Cashman(Acting Chief Scientific Officer)
Co-investorsLeaps by BayerRA Capital
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge
GREGORY WINTER(Director)KEVIN LEE(Executive Officer, Director)NIGEL CROCKETT(Executive Officer)NICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)MICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalLongwood FundSR One Capital ManagementSV Health Investors
HealthtechFremont, US
Anton Clifford(Executive Officer)James Leech(Executive Officer)Christopher Gleason(Executive Officer)Kevin K. Sidow(Executive Officer, Director)
BoardJoshua Makower(Director)Shahzad Malik(Director)in
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Runway Growth CapitalAdvent Life SciencesGBS Venture Partners Ltd.Gilde Healthcare
Neuspera Medical develops an integrated sacral neuromodulation (iSNM) system that implants a smart neurostimulator near the sacral nerve to treat urinary urge incontinence, a symptom of overactive bladder.
BiotechHealthtechMedical DevicesSan Jose, US
Alexander Yeh(Founder)inMilton M. Morris(Executive Officer, Director)Dave Van Meter(Chief Executive Officer)Steve Paul(Chief Commercial Officer)
Co-investorsCerity Partners VenturesForeground CapitalPortfoliaTreo Ventures, LlcWindham Capital PartnersAction Potential Venture Capital Ltd.
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.
BiotechHealthtech
Peter Barrett(Co-founder & Board Member)Tom Wandless(Scientific Founder)Madan Jagasia(Chief Executive Officer)Parameswaran Hari(Chief Medical Officer)Julie Feder(Chief Financial Officer)Dana Alexander(Chief Technical Officer)
Co-investorsAtlas VentureTCG Crossover
BiotechWaltham, US
James W. Broderick(Executive Officer, Director)John Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)
BoardJens Eckstein(Director)
Co-investorsSR One Capital ManagementPfizer VenturesTakeda Ventures
Septerna develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform.
BiotechDeep TechSouth San Francisco, US
Ran Xiao(Executive Officer)Elizabeth Bhatt(Executive Officer)Abraham Bassan(Director)Samira Shaikhly(Executive Officer)
BoardAlan Ezekowitz(Director)Jeffrey Tong(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSamsara BioCapitalThird Rock Ventures
Clinical-stage biotechnology company developing novel antibody-based therapies to transform cancer treatment.
BiotechCulver City, US
Mark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)Amit Sinha(Director)Lynn Seely(Director)
Co-investorsOCV PartnersCowen Healthcare InvestmentsGoldman SachsPerceptive Xontogeny Venture
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.